cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease a german perspective成本效益的吡格列酮在2型糖尿病患者macrovascular疾病德国的历史视角.pdfVIP

  • 0
  • 0
  • 约9.48万字
  • 约 12页
  • 2017-09-06 发布于上海
  • 举报

cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease a german perspective成本效益的吡格列酮在2型糖尿病患者macrovascular疾病德国的历史视角.pdf

cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease a german perspective成本效益的吡格列酮在2型糖尿病患者macrovascular疾病德国的历史视角

Cost Effectiveness and Resource Allocation BioMed Central Research Open Access Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective 1 2 2 Werner A Scherbaum , G

您可能关注的文档

文档评论(0)

1亿VIP精品文档

相关文档